Cargando…

Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study

Objective: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CRT) in multiple primary cancers (MPC) of the upper digestive tract in esophageal squamous cell carcinoma (ESCC). Methods: In a screening of 1193 consecutive patients diagnosed with ESCC and received radiotherapy, 53 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qi-Wen, Zhu, Yu-Jia, Zhang, Wen-Wen, Yang, Han, Liang, Yao, Hu, Yong-Hong, Qiu, Bo, Liu, Meng-Zhong, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370500/
https://www.ncbi.nlm.nih.gov/pubmed/28367236
http://dx.doi.org/10.7150/jca.17408
_version_ 1782518251540971520
author Li, Qi-Wen
Zhu, Yu-Jia
Zhang, Wen-Wen
Yang, Han
Liang, Yao
Hu, Yong-Hong
Qiu, Bo
Liu, Meng-Zhong
Liu, Hui
author_facet Li, Qi-Wen
Zhu, Yu-Jia
Zhang, Wen-Wen
Yang, Han
Liang, Yao
Hu, Yong-Hong
Qiu, Bo
Liu, Meng-Zhong
Liu, Hui
author_sort Li, Qi-Wen
collection PubMed
description Objective: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CRT) in multiple primary cancers (MPC) of the upper digestive tract in esophageal squamous cell carcinoma (ESCC). Methods: In a screening of 1193 consecutive patients diagnosed with ESCC and received radiotherapy, 53 patients presenting synchronous MPC in the upper digestive tract were retrospectively investigated. 53 consecutive patients with esophageal non-multiple primary cancer (NPC), matched by stage, age and sex, served as control. All of the patients received concurrent CRT. The median radiation dose was 60 Gy. Chemotherapy regimens were based on platinum and/or 5-fluorouracil. Clinical outcomes and treatment toxicities were compared. Results: Clinic-pathologic characteristics were well balanced between groups. MPC mostly located in esophagus (43, 81.8%), followed by hypopharynx (8, 15.1%) and stomach (2, 3.8%). In MPC and NPC patients, 94.3% and 96.2% completed the intended treatment. The immediate response rate was 73.6% vs 75.5%, with complete response rate of 11.3% vs 24.5% and partial response rate of 62.3% vs 51.0%. Two-year overall survival (OS), progression-free survival (PFS), locoregional progression-free survival (LRPFS) and distant progression-free survival (DPFS) were 52.2% vs 68.9% (p=0.026), 32.9% vs 54.0% (p=0.032), 60.8% vs 87.8% (p=0.002) and 64.0% vs 70.8% (p=0.22), respectively. Acute grade 3-4 toxicities were observed in 64.2% vs 54.7%, significantly higher in radiation esophagitis (49.1% vs 28.3%, p<0.001), and mucositis (11.3% vs 00p=0.027). Conclusions: Compared with matched NPC, ESCC accompanied with synchronous MPC was related to significantly impaired survival, elevated risk of locoregional disease progression and higher incidence of severe esophagitis and mucositis, following concurrent chemoradiotherapy. Future study on reasons for decreased efficacy of chemoradiotherapy will help to optimize treatment. Advanced radiation techniques may play a role in protecting normal tissues and reduce acute toxicities.
format Online
Article
Text
id pubmed-5370500
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-53705002017-03-31 Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study Li, Qi-Wen Zhu, Yu-Jia Zhang, Wen-Wen Yang, Han Liang, Yao Hu, Yong-Hong Qiu, Bo Liu, Meng-Zhong Liu, Hui J Cancer Research Paper Objective: To evaluate the efficacy and toxicity of concurrent chemoradiotherapy (CRT) in multiple primary cancers (MPC) of the upper digestive tract in esophageal squamous cell carcinoma (ESCC). Methods: In a screening of 1193 consecutive patients diagnosed with ESCC and received radiotherapy, 53 patients presenting synchronous MPC in the upper digestive tract were retrospectively investigated. 53 consecutive patients with esophageal non-multiple primary cancer (NPC), matched by stage, age and sex, served as control. All of the patients received concurrent CRT. The median radiation dose was 60 Gy. Chemotherapy regimens were based on platinum and/or 5-fluorouracil. Clinical outcomes and treatment toxicities were compared. Results: Clinic-pathologic characteristics were well balanced between groups. MPC mostly located in esophagus (43, 81.8%), followed by hypopharynx (8, 15.1%) and stomach (2, 3.8%). In MPC and NPC patients, 94.3% and 96.2% completed the intended treatment. The immediate response rate was 73.6% vs 75.5%, with complete response rate of 11.3% vs 24.5% and partial response rate of 62.3% vs 51.0%. Two-year overall survival (OS), progression-free survival (PFS), locoregional progression-free survival (LRPFS) and distant progression-free survival (DPFS) were 52.2% vs 68.9% (p=0.026), 32.9% vs 54.0% (p=0.032), 60.8% vs 87.8% (p=0.002) and 64.0% vs 70.8% (p=0.22), respectively. Acute grade 3-4 toxicities were observed in 64.2% vs 54.7%, significantly higher in radiation esophagitis (49.1% vs 28.3%, p<0.001), and mucositis (11.3% vs 00p=0.027). Conclusions: Compared with matched NPC, ESCC accompanied with synchronous MPC was related to significantly impaired survival, elevated risk of locoregional disease progression and higher incidence of severe esophagitis and mucositis, following concurrent chemoradiotherapy. Future study on reasons for decreased efficacy of chemoradiotherapy will help to optimize treatment. Advanced radiation techniques may play a role in protecting normal tissues and reduce acute toxicities. Ivyspring International Publisher 2017-02-11 /pmc/articles/PMC5370500/ /pubmed/28367236 http://dx.doi.org/10.7150/jca.17408 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Li, Qi-Wen
Zhu, Yu-Jia
Zhang, Wen-Wen
Yang, Han
Liang, Yao
Hu, Yong-Hong
Qiu, Bo
Liu, Meng-Zhong
Liu, Hui
Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study
title Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study
title_full Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study
title_fullStr Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study
title_full_unstemmed Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study
title_short Chemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study
title_sort chemoradiotherapy for synchronous multiple primary cancers with esophageal squamous cell carcinoma: a case-control study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370500/
https://www.ncbi.nlm.nih.gov/pubmed/28367236
http://dx.doi.org/10.7150/jca.17408
work_keys_str_mv AT liqiwen chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT zhuyujia chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT zhangwenwen chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT yanghan chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT liangyao chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT huyonghong chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT qiubo chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT liumengzhong chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy
AT liuhui chemoradiotherapyforsynchronousmultipleprimarycancerswithesophagealsquamouscellcarcinomaacasecontrolstudy